Gilead Sciences SG&A increased by 32.2% to $1.79B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.9%, from $1.91B to $1.79B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 2.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
is_selling_general_and_administrativeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.35B | $1.19B | $1.65B | $1.08B | $1.36B | $1.21B | $2.02B | $1.32B | $1.85B | $1.32B | $1.61B | $1.38B | $1.38B | $1.43B | $1.91B | $1.26B | $1.37B | $1.36B | $1.79B |
| QoQ Change | — | -11.9% | +38.7% | -34.4% | +25.3% | -10.6% | +66.5% | -34.7% | +40.2% | -28.9% | +22.2% | -14.4% | +0.1% | +4.1% | +33.0% | -34.0% | +8.5% | -0.6% | +32.2% |
| YoY Change | — | — | — | — | +0.4% | +1.9% | +22.4% | +21.8% | +36.3% | +8.4% | -20.4% | +4.2% | -25.5% | +9.0% | +18.6% | -8.5% | -0.9% | -5.3% | -5.9% |
Range$1.08B – $2.02B
CAGR+6.5%
Avg YoY Growth+3.8%
Median YoY Growth+1.9%
SG&A at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's sg&a?
- Gilead Sciences (GILD) reported sg&a of $1.79B in Q4 2025.
- How has Gilead Sciences's sg&a changed year-over-year?
- Gilead Sciences's sg&a decreased by 5.9% year-over-year, from $1.91B to $1.79B.
- What is the long-term trend for Gilead Sciences's sg&a?
- Over 4 years (2021 to 2025), Gilead Sciences's sg&a has grown at a 2.4% compound annual growth rate (CAGR), from $5.25B to $5.77B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.